公开(公告)号：KR1020090039513A

公开(公告)日：2009-04-22

申请号：KR1020070105205

申请日：2007-10-18

Applicant: 재단법인서울대학교산학협력재단

Inventor： 조종수 ,  전희선 ,  강호림 ,  유미경 ,  김유경 ,  최윤재

IPC: A61K9/22 ,  A61K47/36

CPC classification number: C08B37/003 ,  A61K9/0053 ,  A61K9/167 ,  A61K47/36

Abstract: A chitosan particle coated with thiolated eudragit, in which the BSA(Bovine Serum Albumin) is soaked, is provide to use as a delivery agent of a drug by oral administration. A manufacturing method of a chitosan particulate for a protein oral administration coated with eudragit having a pH sensitivity and mucous adhesive property comprises: a step of sonicating and centrifuging the chitosan solution to obtain chitosan particle; a step of adding BSA to the chiotsan particle, suspending to distribute the chitosan particle, and stirring at 35-40°C for 12-24 hours to soak the BSA into chitosan particle; and a step of adding the thiolated eudragit solution to the BSA-soaked chitosan particle, stirring and centrifuging to obtain the chitosan particle coated with BSA-dipped thiolated eudragit. The addition rate of the thiolated eudragit solution to the BSA-dipped chitosan particle is 1:1-1:4.

Abstract translation: 将BSA（牛血清白蛋白）浸泡的硫蛋白包被的壳聚糖颗粒通过口服给药用作药物的递送剂。 用于具有pH敏感性和粘性粘合性质的用于蛋白质口服给药的壳聚糖颗粒的制造方法包括：超声处理和离心壳聚糖溶液以获得壳聚糖颗粒的步骤; 将BSA加入到悬浮颗粒中，悬浮以分散壳聚糖颗粒，并在35-40℃下搅拌12-24小时以将BSA浸泡到壳聚糖颗粒中; 将硫醇化的eudragit溶液加入到BSA-浸泡的壳聚糖颗粒中，搅拌和离心以获得涂布有BSA-浸渍的硫苷酸脱乙酰壳多糖的壳聚糖颗粒的步骤。 硫苷酸脱乙酰壳多糖溶液对BSA-浸渍壳聚糖颗粒的添加速率为1:1-1:4。

公开(公告)号：KR1020090088184A

公开(公告)日：2009-08-19

申请号：KR1020080013577

申请日：2008-02-14

Applicant: 재단법인서울대학교산학협력재단

Inventor： 조종수 ,  전희선 ,  강호림 ,  유미경 ,  김유경 ,  최윤재

IPC: A61K9/16 ,  A61K9/14 ,  A61K47/30

CPC classification number: A61K9/1617 ,  A61K9/0053 ,  A61K9/113 ,  A61K9/1682 ,  A61K38/385

Abstract: A thiolated eutragit microsphere drug carrier for oral administration is provided to minimize the reduction of drug at low pH concentration and enhance the availability of drug. A method for manufacturing a thiolated eutragit microsphere drug carrier for oral administration comprises: a step of reacting L-cysteine hydrochloride with eutragit to obtain thiolated eutragit; a step of resolving thiolated eutragit in organic solvent to make thiolated eutragit solution; a step of resolving protein drug in distilled water to make drug solution; a step of adding protein drug solution in thiolated eutragit solution and treating with ultrasonic wave; a step of adding surfactant solution; and a step of solvent from water/oil/water emulsion and centrifuging.

Abstract translation: 提供用于口服给药的硫醇化微球药物载体以使药物在低pH浓度下的还原最小化并增加药物的可用性。 用于口服给药硫醇化微球药物载体的方法包括：使L-半胱氨酸盐酸盐与eutragit反应获得硫醇化的步骤; 在有机溶剂中分解硫醇化反应产生硫醇化溶液的步骤; 在蒸馏水中分解蛋白质药物制成药物溶液的步骤; 在硫醇化溶液中加入蛋白质药液并用超声波处理的步骤; 添加表面活性剂溶液的步骤; 和水/油/水乳液和离心的溶剂步骤。